, Volume 48, Issue 2, pp 137–152 | Cite as

The Clinical Potential of Ademetionine (S-Adenosylmethionine) in Neurological Disorders

  • T. Bottiglieri
  • Keith Hyland
  • Edward H. Reynolds
Review Article


This review focuses on the biochemical and clinical aspects of methylation in neuropsychiatrie disorders and the clinical potential of their treatment with ademetionine (S-adenosylmethionine; SAMe). SAMe is required in numerous transmethylation reactions involving nucleic acids, proteins, phospholipids, amines and other neurotransmitters. The synthesis of SAMe is intimately linked with folate and vitamin B12 (cyanocobalamin) metabolism, and deficiencies of both these vitamins have been found to reduce CNS SAMe concentrations. Both folate and vitamin B12 deficiency may cause similar neurological and psychiatric disturbances including depression, dementia, myelopathy and peripheral neuropathy. SAMe has a variety of pharmacological effects in the CNS, especially on monoamine neurotransmitter metabolism and receptor systems. SAMe has antidepressant properties, and preliminary studies indicate that it may improve cognitive function in patients with dementia. Treatment with methyl donors (betaine, methionine and SAMe) is associated with remyelination in patients with inborn errors of folate and C-l (one-carbon) metabolism. These studies support a current theory that impaired methylation may occur by different mechanisms in several neurological and psychiatric disorders.


Multiple Sclerosis Folate Homocysteine Inborn Error Methionine Adenosyltransferase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mudd SH, Cantoni GL. Biological transmethylation methyl-group neogenesis and other one carbon metabolic reactions dependant upon tetrahydofolic acid. In: Florkin M, Stotz EH, editors. Comprehensive biochemistry. Vol. 15. Amsterdam: Elsevier, 1964: 147Google Scholar
  2. 2.
    Smthyies JR. Recent advances in the biochemistry of psychosis. Lancet 1960; 2: 1287–9Google Scholar
  3. 3.
    Cohen S, Nichols A, Wyatt R. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol Psychiatry 1974; 8: 209–25PubMedGoogle Scholar
  4. 4.
    Checkley SA, Oon MCH, Rodnight R, et al. Urinary excretion of dimethyltryptamine in liver disease. Am J Psychiatry 1979; 135: 439–41Google Scholar
  5. 5.
    Smthyies JR, Morin RD, Brown GB. Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry. Biol Psychiatry 1979; 14: 549–56Google Scholar
  6. 6.
    Levi RN, Waxman S. Schizophrenia, epilepsy, cancer, methionine, and folate metabolism: pathogenesis of schizophrenia. Lancet 1975; 2: 11–3PubMedGoogle Scholar
  7. 7.
    Smythies JR. The transmethylation and one-carbon cycle hy pothesis of schizophrenia. Psychol Med 1983; 13: 711–14PubMedGoogle Scholar
  8. 8.
    Tolbert LC, Monti JA, O’Shields H, et al. Defects in transmethylation and membrane lipids in schizophrenia. Psycho-pharmacol Bull 1983; 19: 594–9Google Scholar
  9. 9.
    Sargent T, Kusubov N, Taylor SE, et al. Tracer kinetic evidence for abnormal methyl metabolism in schizophrenia. Biol Psychiatry 1992; 32: 1078–90PubMedGoogle Scholar
  10. 10.
    Botez MI, Reynolds EH, editors. Folic acid in neurology, psychiatry and internal medicine. New York: Raven Press, 1979Google Scholar
  11. 11.
    Reynolds EH. Neurological aspects of folate and vitamin B12 metabolism. Clin Haematol 1976; 5: 661–96PubMedGoogle Scholar
  12. 12.
    Shorvon SD, Carney MWP, Chanarin I, et al. The neuropsychiatry of megaloblastic anaemia. BMJ 1980; 281: 1036–42PubMedGoogle Scholar
  13. 13.
    Janicak PG, Lipinski J, Davis JM. S-adenosylmethionine in depression: a literature review and preliminary report. Alabama J Med Sei 1988; 25: 306–13Google Scholar
  14. 14.
    Friedel HA, Goa KL, Benfield P. S-adenosyl-L-Methionine: a review of its therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989; 38: 389–416PubMedGoogle Scholar
  15. 15.
    Cantoni GL. S-adenosylmethionine; a new intermediate formed enzymatically from L-methionine and adenosinetriphosphate. J Biol Chem 1953; 204: 403–16Google Scholar
  16. 16.
    Finkelstein JD, Kyle WE, Martin J, et al. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun 1975; 66: 81–7PubMedGoogle Scholar
  17. 17.
    Mckeever MP, Molloy AM, Weir DG, et al. Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci 1991; 81: 551–6PubMedGoogle Scholar
  18. 18.
    Weir DG, Keating JN, McParhin J, et al. Methylation deficiency causes vitamin B12 associated neuropathy in the pig. J Neurochem 1988; 51: 1949–52PubMedGoogle Scholar
  19. 19.
    Hyland K, Smith I, Bottiglieri T, et al. Demyelination and decreased S-adenosylmethionine in 5, 10-methylentetrahydrfolate reductase deficiency. Neurol 1988; 38: 459–62Google Scholar
  20. 20.
    Surtees R, Leonard J, Austin S. Association of demyelination with deficiency of cerebrospinal fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 1991; 338: 1550–4PubMedGoogle Scholar
  21. 21.
    Cantoni GL. The centrality of S-adenosylhomocysteine in the regulation of the biological utilization of S-adenosylmethionine. In: Borchardt C, Ueland PM, editors. Biological methylation and drug design: experimental and clinical roles of SAM. Clifton: Humana Press Inc., 1986: 227–37Google Scholar
  22. 22.
    Kutzbach C, Stokstad ELR. Mammalian methylenetetra-hydrofolate reductase: partial purification properties, and inhibition by S-adenosylmethionine. Biochim Biophys Acta 1971; 250: 459–77PubMedGoogle Scholar
  23. 23.
    Seihub J, Miller JW. The pathogenesis of homocysteine: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J ClinNutr 1992; 55: 131–8Google Scholar
  24. 24.
    Wood JH. Neurobiology of CSF. New York: Plenum Press, 1980Google Scholar
  25. 25.
    Mann S, Hill MW. Activation and inactivation of striatal tyrosine hydroxylase: the effects of PH, ATP, and cyclic AMP, S-adenosylmethionine and S-adenosylhomocystene. Bio-chem Pharmocol 1983; 32: 3369–74Google Scholar
  26. 26.
    Algeri S, Catto E, Curico M, et al. Changes in rat brain noradrenaline and serotonin metabolism after dministration of S-adenosylmethionine. In: Zappia V, Usdin E, Salvatore S, editors. Biochemical and pharmacological roles of adenosylmethionine and the central nervous system. New York: Pergamon Press, 1979: 81–7Google Scholar
  27. 27.
    Curico M, Catto E, Stramentinoli G, et al. Effect of SAMe on 5HT metabolism in rat brain. Prog Neuropysychopharmacol 1978; 2: 65–71Google Scholar
  28. 28.
    Otero-Losada ME, Rubio MC. Acute changes in 5HT metabolism after S-adenosylmethionine administration. Gen Pharmacol 1989; 20: 403–6PubMedGoogle Scholar
  29. 29.
    Otero-Losada ME, Rubio MC. Acute effects of S-adenosylmethionine on catecholaminergic central function. Eur J Pharmacol 1990; 163: 353–6Google Scholar
  30. 30.
    Fonlupt P, Roy C, Pacheco H. Phospholipid methylation and noradrenaline exchanges in a synatosomal preparation from the rat brain. J Neurochem 1982; 38: 1615–20PubMedGoogle Scholar
  31. 31.
    Schatz RA, Stramentinoli G, Sellinger OZ. Decreased cerebral catabolism of 13Hriistamine in vivo after S-adenosylmethionine administration. J Pharmacol Exp Ther 1981; 216: 118–24PubMedGoogle Scholar
  32. 32.
    Bidard JN, Darmenton P, Cronenberger L, et al. Effet de la S-adenosyl-L-methionine sur le catabolisme de la dopamine. J Pharmacol 1977; 8: 83–93Google Scholar
  33. 33.
    Agnoli A, Ruggieri S, Cerone GG, et al. The dopamine hypothesis of depression: results of treatment with dopaminergic drugs. In: Grattini S, editor. Depressive disorders. Stuttgart: FK Schatauer Verlag, 1977: 447–58Google Scholar
  34. 34.
    Bottiglieri T, Laundy M, Martin R, et al. S-adenosylmethionine influences monoamine metabolism [letter]. Lancet 1984; 2: 224PubMedGoogle Scholar
  35. 35.
    Bottiglieri T, Carney MWP, Edeh J, et al. A biochemical study of depressed patients receiving S-adenosylmethionine (SAM). In: Borchardt C, Ueland PM, editors. Biological methylation and drug design: experimental and clinical roles of SAM. Clifton: Humana Press Inc., 1986: 327–38Google Scholar
  36. 36.
    Yamamura HI, Enna SJ, editors. Neurotransmitter receptors: part 2. Biogenic amines. London and New York: Chapman, 1981Google Scholar
  37. 37.
    Sherer MA, Cantoni GL, Golden RN, et al. Effects of S-ad-enosyl-methionine on plasma norepinephrine, blood pressure, and heart rate in healthy volunteers. Psychiatry Res 1986; 17: 111–8PubMedGoogle Scholar
  38. 38.
    Agnoli A, Martucci N, Manna V. On the the antidepressant effect of SAMe: clinical and pharmaco-EEG study with SAMealone and in association with a beta-2 stimulant drug, phenoterole. Clin Neuropharm 7: 104–5, 1984Google Scholar
  39. 39.
    Cohen B, Stramentinoli G, Sosa AL, et al. Effects of the novel antidepressant S-adenosylmethionine on ai- and β-ad-renoreceptors in rat brain. Eur J Pharmacol 1989; 170: 201–7PubMedGoogle Scholar
  40. 40.
    Cimino M, Vantini G, Algeri S. Age-related modification of dopaminergic and beta-adrenergic receptor system: restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci 1984; 34: 2029–39PubMedGoogle Scholar
  41. 41.
    Hirata F, Strittmatter WJ, Axelrod J. β-adrenergic receptor agonists increase phospholipid methylation, membrane fluidity and β-adrenergic receptor-adenylate cyclase coupling. Proc Natl Acad Sei 1979; 76: 368–72Google Scholar
  42. 42.
    Di Perri B, Calderini G, Battistella A. Phospholipid methylation increases [3Hldiazepam and [3H]GAB A binding in membrane preparations from rat cerebellum. J Neurochem 1983; 41: 302–8PubMedGoogle Scholar
  43. 43.
    Muccioli G, Scordamaglia A, Bertacco S, et al. Effect of S-adenosyl-L-methionine on brain muscarinic receptors of aged rats. Eur J Pharmacol 1992; 227: 293–9PubMedGoogle Scholar
  44. 44.
    Muccioli G, DiCarlo R. S-adenosylmethionine restores prolactin receptors in the aged rabbit brain. Eur J Pharmacol 1989; 166: 223–30PubMedGoogle Scholar
  45. 45.
    Wurtman RJ, Rose S, Matthyse S. L-dihydroxyphenylalanine effect on S-adenosylmethionine in brain. Science 1970; 169: 395–7PubMedGoogle Scholar
  46. 46.
    Surtees R, Hyland K. L-3, 4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosyl-methionine concentrations in humans. J Neurol Neurosur Psychiatry 1990; 53: 569–72Google Scholar
  47. 47.
    Keating JN, Trimble KC, Mulcahy et al. Evidence of brain methyltransferase inhibition and early brain involvement in HIV positive patients. Lancet 1991; 337: 935–9PubMedGoogle Scholar
  48. 48.
    Surtees R, Hyland K, Smith I. Central-nervous-system methyl group metabolism in children with neurological complications of HIV infection. Lancet 1990; 335: 619–21PubMedGoogle Scholar
  49. 49.
    Hyland K, Surtees RAH, Rodeck C, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurol 1992; 42: 1980–8Google Scholar
  50. 50.
    Pall HS, Surtees R, Sturman SG, et al. S-adenosylmethionine in cerebrospinal fluid in Parkinson’s disease (PD) [abstract]. Neurology 1992; 42: 283Google Scholar
  51. 51.
    Mayeux R. Depression in the patient with Parkinson’s disease. J Clin Psychiatry 1990; 51: 20–3PubMedGoogle Scholar
  52. 52.
    Meitzer H. Serotonergic function in depression. Br J Psychiatry 1989; 155: 25–31Google Scholar
  53. 53.
    Siever LJ, Khan RS, Lawlor BA, et al. Critical issues in defining the role of serotonin in psychiatric disorders. Am Soc Pharmacol Exp Ther 1991; 43: 509–25Google Scholar
  54. 54.
    Jellinger K. Overview of morphological changes in Parkinson’s disease. In: Yahr MD, Bergmann KJ, editors. Advances in neurology: Parkinson’s disease. New York: Raven Press, 1986: 1–19Google Scholar
  55. 55.
    Ruberg M, Agid Y. Dementia in Parkinson’s disease. In: Iverson L, Iverson SD, Synder SH, editors. Handbook of psychophar-macology, Vol. 20. Psychopharmacology of the aging nervous system. New York: Plenum Press, 1988: 157–206Google Scholar
  56. 56.
    Mayeux R. The serotonin hypothesis of depression in Parkinson’s disease. J Clin Psychiatry 1990; 53: 163–6Google Scholar
  57. 57.
    Mindham RHS, Marsden CD, Parkes JD. Psychiatric symptoms during L-dopa therapy of Parkinson’s disease and their relationship to physical disability. Psychol Med 1976; 6: 23–33PubMedGoogle Scholar
  58. 58.
    Barbeau A. L-dopa therapy of Parkinson’s disease: a critical review of nine years experience. Can Med Assoc J 1969; 101: 791–800Google Scholar
  59. 59.
    Maruyama W, Naoi M, Takahashi A, et al. The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies. J Neural Transm Gen Sect 1992; 90: 183–97PubMedGoogle Scholar
  60. 60.
    Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depression in patients with Parkinson’s disease: a double blind, crossover study versus placebo. Curr Ther Res 1990; 48: 154–60Google Scholar
  61. 61.
    Crellin R, Bottiglieri T, Reynolds EH. Folates and Psychiatric Disorders. Drugs 1993; 45: 623–36PubMedGoogle Scholar
  62. 62.
    Bell IR, Edman JS, Marby DW, et al. Vitamin B12 and folate status in acute geropsychiatric inpatients: affective and cognitive characteristics of a vitamin non-deficient population. Biol Psychiatry 1990; 27: 125–37PubMedGoogle Scholar
  63. 63.
    Ikeda T, Furukawa Y, Mashimoto S, et al. Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer’s dementia. Acta Psychiatr Scand 1990; 82: 327–9PubMedGoogle Scholar
  64. 64.
    Nijst TQ, Weavers RA, Schoonderwaldt HC, et al. Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological and psychiatric patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry 1990; 53: 951–4PubMedGoogle Scholar
  65. 65.
    Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 53: 1990; 1096–8PubMedGoogle Scholar
  66. 66.
    Reynolds EH, Godfrey P, Bottiglieri T, et al. S-adenosylmethionine and Alzheimer’s disease [abstract]. Neurol 1989; 39 Suppl. 1: 397Google Scholar
  67. 67.
    Reynolds EH, Carney MWP, Toone BK, et al. Transmethylation and neuropsychiatry. In: Mato J, editor. Biochemical, pharmacological and clinical aspects of transmethylation. Cell Biology Reviews 1987; 2: 93–102Google Scholar
  68. 68.
    Cohen BM, Satlin A, Zubenko GS. S-adenosylmethionine in the treatment of Alzheimer’s dementia. J Clin Psychopharmacol 1988; 8: 43–7PubMedGoogle Scholar
  69. 69.
    Williams RS, Matthysse S. Age-related changes in Down syndrome brain and the cellular pathology of Alzheimer’s disease. Prog Brain Res 1986; 70: 49–67PubMedGoogle Scholar
  70. 70.
    Gericke GS, Hesseling PB, Brink S, et al. Leucocyte ultrastructure and folate metabolism in Down’s syndrome. S Afr Med J 1977; 51: 369–74PubMedGoogle Scholar
  71. 71.
    Hewwitt KE, Carter G, Jancar J. Ageing in Down’s syndrome. Br J Psychiatry 1985; 147: 58–62Google Scholar
  72. 72.
    Lejeune J, Rethore MO, de Blois MC, et al. Metabolism of monocarbons and trisomy 21: sensitivity to methotrexate. Ann Genet 1986; 29: 16–19PubMedGoogle Scholar
  73. 73.
    Chadefaux B, Rethore MO, Raoul O, et al. Cystathionine beta synthetase: gene dosage effect in trisomy 21. Biochem Biophys Res Commun 1985; 128: 40–4PubMedGoogle Scholar
  74. 74.
    Chadefaux B, Ceballos I, Hamet M, et al. Is absence of atheroma in Down’s syndrome due to decreased homocysteine levels? [letter]. Lancet 1988; 2: 741PubMedGoogle Scholar
  75. 75.
    Reynolds EH. Interictal psychiatric disorders. In: Smith D, Treiman D, Trimble MR, editors. Advances in neurology. New York: Raven Press, 1991: 44–58Google Scholar
  76. 76.
    Reynolds EH. Effects of folic acid on the mental state and fit frequency of drug treated epileptic patients. Lancet 1967; 1: 1086–8PubMedGoogle Scholar
  77. 77.
    Trimble MR, Corbett JA, Donaldson D. Folic acid and mental symptoms in children with epilepsy. J Neurol Neurosurg Psychiatry 1980; 43: 103–4Google Scholar
  78. 78.
    Robertson MM, Trimble MR. Depressive illness in patients with epilepsia: a review. Epilepsia 1983; 24: 109–16Google Scholar
  79. 79.
    Rodin E, Schmaltz S. Folate levels in epileptic patients. In: Parsonage M, Grant RHE, Craig AG, Ward AA, editors. Advances in epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983; 143–53Google Scholar
  80. 80.
    Edeh J, Toone BK. Antiepileptic therapy, folate deficiency and psychiatric morbidity: a general practice survey. Epilepsia 1985; 26: 434–40PubMedGoogle Scholar
  81. 81.
    Reynolds EH. Anticonvulsants, folic acid and epilepsy. Lancet 1973; 1: 1376–8PubMedGoogle Scholar
  82. 82.
    Hommes OR, Hollinger JL, Jansen NJT, et al. Convulsant properties in folate compounds: some considerations and speculations. In: Botez MI, Reynolds EH, editors. Folic acid in neurology, psychiatry and internal medicine. New York: Raven Press, 1979: 285–316Google Scholar
  83. 83.
    Kaijima M, Riche D, Rousseva S, et al. Electroencehalo-graphioc, behavioural and histopathological features of seizures induced by intra-amygdala application of folic acidincats. Exp Neurol 1984; 86: 313–21PubMedGoogle Scholar
  84. 84.
    Reynolds EH, Bottiglieri T, Laundy M, et al. Vitamin B12 metabolism in multiple sclerosis. Arch Neurol 1992; 42: 649–52Google Scholar
  85. 85.
    Crellin RF, Bottiglieri T, Reynolds EH. Multiple sclerosis and macrocytosis. Acta Neurol Scand 1991; 81: 388–91Google Scholar
  86. 86.
    Najimal-Din AS, Khojali M, Habbosh H, et al. Marcocytosis in multiple sclerosis: a study of 82 de novo Arab patients. J Neurol Neurosurg Psychiatry 1991; 54: 415–6Google Scholar
  87. 87.
    Chanarin I. The megaloblastic anaemias. 2nd ed. Oxford: Blackwell Medical Publishers, 1979; 187–97Google Scholar
  88. 88.
    Reynolds EH. Multiple sclerosis and vitamin B12 metabolism. J Neuroimmunol 1992; 40: 225–30PubMedGoogle Scholar
  89. 89.
    Pincus JH. Folic acid deficiency: a cause of subacute combined system degeneration. In: Botez MI, Reynolds EH, editors. Folic acid in neurology, psychiatry and internal medicine. New York: Raven Press, 1979; 427–33Google Scholar
  90. 90.
    Lever EG, Elwes RDC, Williams A, Reynolds EH. Subacute combined degeneration of the cord due to folate deficiency: response to methyl folate treatment. J Neurol Neurosurg Psychiatry 1985; 49: 1203–7Google Scholar
  91. 91.
    Grandy G, Jacobson W, Sidman R. Inhibition of a transmethylation reaction in the central nervous system — an experimental model for subacute combined degeneration of the cord. J Physiology 1973; 233: IP–3PGoogle Scholar
  92. 92.
    Jacobson W, Gandy G, Sidman RL. Experimental subacute combined degeneration of the cord in mice. J Pathol 1973; 109 Suppl.: P13–14PubMedGoogle Scholar
  93. 93.
    Lee CC, Surtees R, Duchen LW. Distal motor axonopathy and central nervous system myelin vacuolation caused by cycloleucine, an inhibitor of methionine adenosyltransferase. Brain 1992; 115: 935–55PubMedGoogle Scholar
  94. 94.
    Scott JM, Winn J, Wilson P, et al. Pathogenesis of subacute combined degeneration: a result of methyl group deficiency. Lancet 1981; 2: 334–7PubMedGoogle Scholar
  95. 95.
    van der Westhuyzen J, Fernandes-Costa F, Metz J. Cobalamin inactivation by nitrous oxide produces severe neurological impairment in fruit bats: protection by methionine and aggravation by folates. Life Sci 1982; 31: 2001–10PubMedGoogle Scholar
  96. 96.
    Molloy AM, Weir DF, Kennedy G, et al. A new high performance liquid chromatographic method for the simultaneous measurement of S-adenosylmethionine and S-adenosyl-homocysteine. Biomed Chromatogr 1990; 4: 257–60PubMedGoogle Scholar
  97. 97.
    Viera-Makings E, Metz J, van der Westhuyzen J, et al. Cobalamin neuropathy: is S-adenosylhomocysteine toxicity a factor?. Biochem J 1990; 266: 707–11Google Scholar
  98. 98.
    Bottiglieri T, Godfery P, Carney MWP, et al. CSF S-adenosylmethionine in neurological and psychiatric patients: effects of treatment with parenteral and oral S-adenosyl-methionine. In: Linnell JC, Bhatt HR, editors. Biomedicine and physiology of vitamin B12. London: Children’s Medical Charity, 1990: 167–74Google Scholar
  99. 99.
    Bleyer CM. Neurological sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981; 65 Suppl. 1: 89–98PubMedGoogle Scholar
  100. 100.
    Price RA. Therapy related central nervous system diseases in children with acute lymphocytic leukaemia. In Mastrangelo R, Poplack DG, editors. Central nervous system leukaemia. Boston: Martinus Nijhoff, 1983: 71–81Google Scholar
  101. 101.
    Kamen BA, Winick N, Lester C, et al. Effect of chronic methotrexate (MTX) treatment on tissue levels of folate and MTX polymutamates (MTXGLUn). Proc Am Assoc Cancer Res 1985; 26: 232Google Scholar
  102. 102.
    Svardal AM, Ueland PM, Berge RK, et al. Effect of methotrexate on homocysteine and other sulfur compounds in tissues of rats fed a normal or a defined, choline-deficient diet. Cancer Chemother Pharmacol 1988; 21: 313–18PubMedGoogle Scholar
  103. 103.
    Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19: 517–24Google Scholar
  104. 104.
    Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158: 1079–83PubMedGoogle Scholar
  105. 105.
    Navia BA, Cho E-W, Petito Ck, et al. The AIDS dementia complex: II. Neuropathology Ann Neurol 1986; 19: 525–35Google Scholar
  106. 106.
    Price RW, Brew BJ, Sidtis J, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239: 586–92PubMedGoogle Scholar
  107. 107.
    Rosenblum MK. Infection of the central nervous system by the human immunodeficiency virus type 1: morphology and relation to syndromes of progressive encephalopathy and myelopathy in patients with AIDS. Pathol Annu 1990; 25 (Pt 1): 117–69PubMedGoogle Scholar
  108. 108.
    Petito CK, Navia BA, Cho E-S, et al. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the aquired immunodeficiency syndrome. New Engl J Med 1985; 312: 874–9PubMedGoogle Scholar
  109. 109.
    Gray F, Gheradi R, Scaravilli F. The neuropathology of the aquired immune deficiency syndrome (AIDS): a review. Brain 1988; 111: 245–66PubMedGoogle Scholar
  110. 110.
    McArthur JC. Neurologic manifestations of AIDS. Medicine 1987; 66: 408–37Google Scholar
  111. 111.
    Lemann W, Cho E-S, Meisen S, Petito C. Neuropathological findings in 104 cases of aquired immune deficiency syndrome (AIDS): an autopsy study. J Neuropath Exp Neurol 1985; 44: 349AGoogle Scholar
  112. 112.
    Lantos PL, McLaughlin JE, Scholtz CL, et al. Neuropathology of the brain in HIV infection. Lancet 1989; 1: 309–11PubMedGoogle Scholar
  113. 113.
    Bottiglieri T. Methylation and neurological complications of HIV infection: the effect of intravenous SAMe administration in restoring CNS methyl group metabolism. Ann Psiquiatr 1992; 8 Suppl. 1: 22–3Google Scholar
  114. 114.
    Allegra CJ, Chabner BA, Tuazon CU, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the aquired immune deficiency syndrome. N Engl J Med 1987; 317: 978–85PubMedGoogle Scholar
  115. 115.
    Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulmethoxazole in patients with the aquired immunodeficiency syndrome. Ann Int Med 1984; 100: 495–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • T. Bottiglieri
    • 1
  • Keith Hyland
    • 1
  • Edward H. Reynolds
    • 2
  1. 1.Metabolic Disease CenterBaylor Research InstituteDallasUSA
  2. 2.Department of NeurologyInstitute of Psychiatry and King’s College School of Medicine and DentistryLondonEngland

Personalised recommendations